Stock 000028 CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials China National Accord Medicines Corporation Ltd.

Equities

000028

CNE0000009N6

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
38.05 CNY +0.58% Intraday chart for China National Accord Medicines Corporation Ltd. +4.28% +31.25%
May. 09 China National Accord Medicines Corporation Ltd. Approves Cash Dividend for the Year 2023 CI
Apr. 25 China National Accord Medicines Corporation Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 18,279 18,131 14,706 13,164 14,937 19,465 - -
Enterprise Value (EV) 1 10,850 15,079 12,430 9,339 12,067 19,019 22,354 16,688
P/E ratio 15.3 x 14 x 11.9 x 9.48 x 10.1 x 12 x 11 x 10.8 x
Yield 0.88% 1.75% 1.62% 2.43% 2.35% 1.98% 1.95% 2.01%
Capitalization / Revenue 0.35 x 0.3 x 0.22 x 0.18 x 0.2 x 0.24 x 0.23 x 0.22 x
EV / Revenue 0.21 x 0.25 x 0.18 x 0.13 x 0.16 x 0.24 x 0.26 x 0.19 x
EV / EBITDA 4.14 x 6.05 x 5.29 x 3.42 x 4.18 x 5.88 x 6.64 x 4.77 x
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Price to Book 1.52 x 1.41 x 1.06 x 0.87 x 0.93 x 1.13 x 1.05 x 0.99 x
Nbr of stocks (in thousands) 556,565 556,565 556,565 556,565 556,565 556,565 - -
Reference price 2 34.89 35.23 28.45 25.30 28.99 38.05 38.05 38.05
Announcement Date 3/24/20 3/15/21 3/15/22 3/15/23 3/15/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 52,046 59,649 68,358 73,443 75,477 80,008 85,748 89,788
EBITDA 1 2,619 2,490 2,349 2,731 2,885 3,237 3,367 3,499
EBIT 1 1,720 2,164 1,952 2,306 2,467 2,716 2,987 3,185
Operating Margin 3.3% 3.63% 2.86% 3.14% 3.27% 3.39% 3.48% 3.55%
Earnings before Tax (EBT) 1 1,857 2,157 1,975 2,311 2,473 2,732 2,939 3,027
Net income 1 1,271 1,402 1,336 1,487 1,599 1,767 1,919 1,968
Net margin 2.44% 2.35% 1.96% 2.02% 2.12% 2.21% 2.24% 2.19%
EPS 2 2.285 2.515 2.400 2.669 2.870 3.172 3.447 3.535
Free Cash Flow - - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 0.3077 0.6154 0.4615 0.6154 0.6800 0.7533 0.7413 0.7650
Announcement Date 3/24/20 3/15/21 3/15/22 3/15/23 3/15/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 18,148 17,151 18,978 18,488 18,826 18,687 19,701 18,198 18,892 19,090 21,205 19,588 20,334 21,052 22,194
EBITDA 520.2 448.4 687.7 599.2 - - - - - - - - - - -
EBIT 359.3 375.1 657.3 531.9 741.8 576.4 718.8 527.8 - - - - - - -
Operating Margin 1.98% 2.19% 3.46% 2.88% 3.94% 3.08% 3.65% 2.9% - - - - - - -
Earnings before Tax (EBT) 375.1 376.8 657.8 534.8 741.7 578.5 713.2 528.8 - - - - - - -
Net income 262.3 252.4 421.9 373.4 439.1 362.2 468 359.4 - - - - - - -
Net margin 1.45% 1.47% 2.22% 2.02% 2.33% 1.94% 2.38% 1.97% - - - - - - -
EPS 2 0.4692 0.4538 0.7538 0.6769 0.7846 0.6538 0.8362 0.6500 0.7300 0.7000 0.9000 0.8800 0.6900 0.7300 0.7500
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 3/15/22 4/19/22 8/30/22 10/24/22 3/15/23 4/17/23 8/28/23 10/26/23 3/15/24 4/25/24 - - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - 2,889 -
Net Cash position 1 7,429 3,051 2,276 3,825 2,870 446 - 2,776
Leverage (Debt/EBITDA) - - - - - - 0.858 x -
Free Cash Flow - - - - - - - -
ROE (net income / shareholders' equity) 10.4% 10.5% 9.29% 9.59% 9.56% 9.48% 9.72% 9.27%
ROA (Net income/ Total Assets) 4.07% 3.83% 3.24% 3.48% - 3.45% 3.67% 3.8%
Assets 1 31,225 36,557 41,189 42,699 - 51,205 52,328 51,792
Book Value Per Share 2 23.00 25.10 26.80 29.00 31.30 33.60 36.10 38.60
Cash Flow per Share 2 3.590 2.700 2.970 4.600 5.280 4.900 3.630 3.790
Capex 1 245 285 369 322 284 402 404 373
Capex / Sales 0.47% 0.48% 0.54% 0.44% 0.38% 0.5% 0.47% 0.42%
Announcement Date 3/24/20 3/15/21 3/15/22 3/15/23 3/15/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for China National Accord Medicines Corporation Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
38.05 CNY
Average target price
39.17 CNY
Spread / Average Target
+2.95%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. Stock China National Accord Medicines Corporation Ltd.
+31.25% 2.69B
MCKESSON CORPORATION Stock McKesson Corporation
+26.57% 76.29B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
-3.27% 23.99B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+10.27% 9.01B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+12.25% 8.67B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-24.34% 7.58B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+12.94% 5.18B
GALENICA AG Stock Galenica AG
+1.79% 4.16B
EBOS GROUP LIMITED Stock EBOS Group Limited
-7.75% 3.98B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
-1.36% 3.63B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. 000028 Stock
  4. Financials China National Accord Medicines Corporation Ltd.